Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Cash (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Change in Cash for 16 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 18778.86% to $23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $140.7 million through Dec 2025, up 284.62% year-over-year, with the annual reading at $140.7 million for FY2025, 284.62% up from the prior year.
  • Change in Cash hit $23.0 million in Q4 2025 for Ani Pharmaceuticals, down from $44.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $94.0 million in Q2 2023 to a low of -$95.1 million in Q3 2024.
  • Historically, Change in Cash has averaged $13.6 million across 5 years, with a median of $9.5 million in 2024.
  • Biggest five-year swings in Change in Cash: tumbled 1567.69% in 2022 and later skyrocketed 18778.86% in 2025.
  • Year by year, Change in Cash stood at $85.0 million in 2021, then crashed by 109.47% to -$8.0 million in 2022, then skyrocketed by 448.36% to $28.0 million in 2023, then plummeted by 100.44% to -$123000.0 in 2024, then surged by 18778.86% to $23.0 million in 2025.
  • Business Quant data shows Change in Cash for ANIP at $23.0 million in Q4 2025, $44.8 million in Q3 2025, and $68.0 million in Q2 2025.